ABO2203
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ABO2203, covering 2025-07-18 to 2026-03-24. Get the full timeline:
Most recent: Clinical Trial Update: A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases [EARLY_Phase 1]